Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study

Kathleen M. Loomes, Robert H. Squires, Deirdre Kelly, Sanjay Rajwal, Nisreen Soufi, Alain Lachaux, Irena Jankowska, Cara Mack, Kenneth D. R. Setchell, Palaniswamy Karthikeyan, Ciara Kennedy, Alejandro Dorenbaum, Nirav K. Desai, Will Garner, Thomas Jaecklin, Pamela Vig, Alexander Miethke, Richard J.

Immune‐mediated liver injury following COVID‐19 vaccination: A systematic review

Akash Roy, Nipun Verma, Surender Singh, Pranita Pradhan, Sunil Taneja, Meenu Singh – 3 May 2022 – Immune‐mediated liver injury (ILI) following coronavirus disease 2019 (COVID‐19) vaccination is not well‐characterized. Therefore, we systematically reviewed the literature on ILI after COVID‐19 vaccination. We searched PubMed, Cochrane, Ovid, Embase, and gray literature to include articles describing ILI following COVID‐19 vaccination. Reports without confirmatory evidence from liver biopsy were excluded. Descriptive analysis, and study quality were reported as appropriate.

AASLD Careers

The American Association for the Study of Liver Diseases is the leading organization of scientists and health care professionals committed to preventing and curing liver disease.

Grace L. Su, MD, FAASLD

President

Grace L. Su, MD, FAASLD

Executive Committee

Grace L. Su, MD, FAASLD is the H. Marvin Pollard Collegiate Professor of Gastroenterology III and Professor of Medicine and Surgery at the University of Michigan Medical School. After completing her undergraduate degree from Yale University and M.D. from the University of Chicago, she pursued her residency and fellowship at the University of Pittsburgh.

As a physician scientist, Dr. Su has a long history of performing clinical and translational research in the area of chronic liver disease and cirrhosis. She is Director of the Morphomics Analysis Group at the University of Michigan, a multidisciplinary collaborative of physicians, biostatisticians and engineers developing methods for analyzing medical imaging. Their work has evolved into analytic morphomics, an innovative high-throughput, highly automated, anatomically indexed platform that measures body composition and organ condition. By linking imaging features to clinical outcomes, they have been able develop highly accurate non-invasive methods for the diagnosis and prognosis of patients with liver disease as well as hepatocellular carcinoma (HCC).

Disclosures of Potential Conflicts of Interest
Dr. Su has nothing to disclose.

W. Ray Kim, MD, MBA, FAASLD

Past President

W. Ray Kim, MD, MBA, FAASLD

Executive Committee

W. Ray Kim, MD, MBA, FAASLD, Professor of Medicine at Mayo Clinic Arizona, Scottsdale, AZ

Dr. Kim received his MD degree from Seoul National University and his MBA from the University of Pennsylvania. Following his medicine residency at Seoul National University and the University of Arkansas, he underwent gastroenterology and hepatology fellowship training at Mayo Clinic in Minnesota.  Subsequently, Ray joined the faculty of the Mayo College of Medicine, where he established his research in prognostication in patients with chronic liver disease.  He is best known for his work in developing, validating and refining the Model for End-stage Liver Disease (MELD) score.

In 2013, he was recruited to Stanford University to lead the Division of Gastroenterology and Hepatology.  Under his leadership, the Division prospered with a significant growth in the breadth and depth of faculty and their expertise, innovative educational programs for the GI, liver and other advanced fellowships, excellence in scientific scholarship and supportive community with emphasis on mentorship and individual growth.

After serving as the GI Chief at Stanford for nearly 11 years, he is returning to Mayo to create the Center for Policy and Outcomes Research in Transplantation (CPORT) based in the Arizona campus.

Subscribe to